文献速递淋巴瘤

霍奇金淋巴瘤患者血清TARC、MDC、IL-10和可溶性CD163水平:SWOG S0816相关性研究

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
PubMed 文献 · Blood · 2019-02-05

该研究在S0816试验中评估了经典霍奇金淋巴瘤(cHL)患者基线、中期PET(PET2)时及治疗后的血清TARC、MDC、IL-10和sCD163水平。EBV阳性与较高的sCD163和IL-10水平及较低的TARC水平相关。基线生物标志物与结局无关,但PET2时sCD163水平与有利的无进展生存(PFS)相关;治疗后TARC、MDC和IL-10与PFS和总生存(OS)相关,调整国际预后评分后仍显著。

要点

  • EBV阳性与较高sCD163和IL-10水平、较低TARC水平相关。
  • PET2时sCD163水平与有利PFS相关,调整PET2状态后仍显著。
  • 治疗后TARC和IL-10与较短PFS和OS显著相关,调整PET结果后仍显著。

核心结论

  • 血清细胞因子水平与cHL结局相关,应在风险适应性cHL试验中进一步研究。

研究设计与样本

  • S0816是一项组间2期应答适应性研究,评估PET2阳性患者接受升级治疗(www.clinicaltrials.gov #NCT00822120)。
  • 共评估559份血清样本,用免疫分析法检测TARC、MDC、IL-10和sCD163,并评估EBV状态。

主要发现

  • EBV阳性与较高的sCD163和IL-10水平及较低的TARC水平相关。
  • 基线生物标志物水平与结局无关。
  • PET2时sCD163水平与有利PFS相关,调整PET2状态后仍显著。
  • 治疗后TARC、MDC和IL-10在单变量分析中与PFS和OS相关,调整国际预后评分后仍显著。
  • 进一步调整治疗结束PET结果后,TARC和IL-10仍与较短PFS和OS显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)-positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hsi ED, Li H, Nixon AB, et al. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. 2019. PMID: 30723079. doi:10.1182/blood-2018-08-870915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。